PMS 601

Drug Profile

PMS 601

Alternative Names: MFH 1; PMS601

Latest Information Update: 06 Dec 2010

Price : $50

At a glance

  • Originator French Atomic Energy Commission; Institut Paris-Sud sur les Cytokines; University of Paris VII
  • Developer BTG; French Atomic Energy Commission; Institut Paris-Sud sur les Cytokines; University of Paris VII
  • Class Antivirals; Piperazines
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 14 Mar 2007 Preclinical development is ongoing
  • 14 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the adverse events and Viral Infections pharmacodynamics section
  • 29 Jun 2000 A preclinical study has been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top